C2 STRATEGIES for BC3 TECHNOLOGIES INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Homeland Security HOM
Federal support for fielding FDA cleared hemostatic wound care technology for military and first responder use. Matters relating to combat casualty care and prehospital hemorrhage control, including Department of Defense medical materiel and Defense Health Agency programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL WAGNER | — |
Budget/Appropriations BUD
Federal support for fielding FDA cleared hemostatic wound care technology for military and first responder use. Matters relating to combat casualty care and prehospital hemorrhage control, including Department of Defense medical materiel and Defense Health Agency programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL WAGNER | — |
Defense DEF
Federal support for fielding FDA cleared hemostatic wound care technology for military and first responder use. Matters relating to combat casualty care and prehospital hemorrhage control, including Department of Defense medical materiel and Defense Health Agency programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL WAGNER | — |
Health Issues HCR
Federal support for fielding FDA cleared hemostatic wound care technology for military and first responder use. Matters relating to combat casualty care and prehospital hemorrhage control, including Department of Defense medical materiel and Defense Health Agency programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL WAGNER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.